We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $791M
1-Year Est. Return 245.83%
This Fund
S&P 500
This Quarter Est. Return
+23.31%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$791M
AUM Growth
+$204M
Cap. Flow
+$24.2M
Cap. Flow %
3.06%
Top 10 Hldgs %
37.34%
Holding
211
New
67
Increased
36
Reduced
24
Closed
63

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$35.2M
2
UTHR icon
United Therapeutics
UTHR
+$14.5M
3
ABVX
Abivax
ABVX
+$9.93M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$9.38M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.02M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$10.4M
2
TERN
Terns Pharmaceuticals
TERN
+$9.58M
3
TGTX icon
TG Therapeutics
TGTX
+$8.47M
4
INCY icon
Incyte
INCY
+$7.74M
5
JNJ icon
Johnson & Johnson
JNJ
+$7.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 66.57%
2 Healthcare 33.4%
3 Consumer Discretionary 0.02%
4 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
176
Eli Lilly
LLY
$1.02T
– –
-6,000
Closed -$6.13M
LPCN icon
177
Lipocine
LPCN
$20.2M
– –
-50,000
Closed -$400K
LQDA icon
178
CALL
Liquidia Corp
LQDA
$6.15B
– –
-662,100
Closed -$25M
LQDA icon
179
PUT
Liquidia Corp
LQDA
$6.15B
– –
-50,000
Closed -$1.89M
LYEL icon
180
PUT
Lyell Immunopharma
LYEL
$352M
– –
-4,100
Closed -$82.2K
MRK icon
181
PUT
Merck
MRK
$371B
– –
-100,000
Closed -$12M
OCGN icon
182
CALL
Ocugen
OCGN
$461M
– –
-300,000
Closed -$543K
OLMA icon
183
CALL
Olema Pharmaceuticals
OLMA
$941M
– –
-84,000
Closed -$1.25M
PASG icon
184
Passage Bio
PASG
$15M
– –
-19,530
Closed -$153K
PRTC
185
DELISTED
PureTech Health
PRTC
– –
-7,924
Closed -$11.3K
QURE icon
186
uniQure
QURE
$3.09B
– –
-31,200
Closed -$817K
RARE icon
187
Ultragenyx Pharmaceutical
RARE
$1.51B
– –
-35,144
Closed -$736K
RCKT icon
188
Rocket Pharmaceuticals
RCKT
$424M
– –
-30,579
Closed -$109K
REPL icon
189
Replimune Group
REPL
$1.42B
– –
-100,660
Closed -$616K
ROIV icon
190
PUT
Roivant Sciences
ROIV
$25.2B
– –
-335,800
Closed -$9.3M
RVMD icon
191
PUT
Revolution Medicines
RVMD
$45B
– –
-125,500
Closed -$12.2M
STTK icon
192
Shattuck Labs
STTK
$681M
– –
-293,664
Closed -$1.89M
TARS icon
193
Tarsus Pharmaceuticals
TARS
$3.98B
– –
-25,942
Closed -$1.82M
TENX icon
194
Tenax Therapeutics
TENX
$72.6M
– –
-179,738
Closed -$2.3M
TERN
195
DELISTED
Terns Pharmaceuticals
TERN
– –
-181,752
Closed -$9.58M
TGTX icon
196
TG Therapeutics
TGTX
$8.57B
– –
-206,928
Closed -$8.47M
TRVI icon
197
Trevi Therapeutics
TRVI
$2.46B
– –
-21,663
Closed -$258K
UTHR icon
198
CALL
United Therapeutics
UTHR
$20.9B
– –
-40,200
Closed -$23.8M
UTHR icon
199
PUT
United Therapeutics
UTHR
$20.9B
– –
-20,000
Closed -$11.9M
VIR icon
200
CALL
Vir Biotechnology
VIR
$1.93B
– –
-88,800
Closed -$796K
5 6 7
8
9

Similar funds

KAS
Kemnay Advisory Services New York $791M AUM 14.14% 1-Year Est. Return
FSAG
Financial Solutions Advisory Group Chicago, Illinois $791M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
BSSFA
Baron Silver Stevens Financial Advisors Boca Raton, Florida $791M AUM 18.81% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $792M AUM 60.81% 1-Year Est. Return
EA
Enclave Advisors Austin, Texas $790M AUM 21.99% 1-Year Est. Return
BBES
Buffalo Business & Estate Services Orchard Park, New York $793M AUM
GEA
Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

Diadema Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Diadema Partners held 211 positions worth $791M, up 35% from $588M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners deployed $24.2M of net new capital in Q2 2026, opening 67 new positions and adding to 36 existing holdings. Its largest new stake was Amgen: 102,701 shares worth $215K.

By sector, the portfolio is most concentrated in Miscellaneous at 67% of assets, up from 62% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $7.4M trimmed.

  • Diadema Partners's largest Q2 2026 buy was Amgen: 102,701 shares worth $215K.
  • Diadema Partners added most to United Therapeutics in Q2 2026, an estimated $14.5M increase.
  • Diadema Partners's biggest Q2 2026 reduction was Johnson & Johnson, cutting an estimated $7.4M.
  • Diadema Partners fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $10.4M.
  • Diadema Partners's ten largest holdings make up 37% of its $791M portfolio in Q2 2026.
  • Diadema Partners opened 67 new positions and closed 63 in Q2 2026.
  • Diadema Partners's portfolio value rose 35% quarter-over-quarter to $791M.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.